Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine versus capecitabine maintenance therapy after first-line chemotherapy for advanced triple-negative breast cancer
ChiCTR1900021218Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Capecitabine maintenance with Vinorelbine maintenance (2 arms). Primary endpoint: Progression-free survival. Started Jan 2019; status: recruiting.
02
Drugs
vinorelbinecapecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR1900021218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021218.